BCL2 and glioblastoma: Because GBM is molecularly heterogeneous and treated under distinct therapeutic contexts, the translational meaning of Bcl-2:beclin-1–related markers (beclin-1, Bcl-2 family expression, LC3/p62, and phospho-patterns) is best interpreted in a subtype-aware framework.